Hepatocellular carcinoma (HCC) surveillance is crucial for early detection and improved survival rates, particularly in at-risk populations such as those with chronic liver disease or cirrhosis. To ensure effective surveillance, minimum standards have been established focusing on patient engagement, diagnostic accuracy, and system efficiency.
Hepatocellular carcinoma (HCC) surveillance is crucial for early detection and improved survival rates, particularly in at-risk populations such as those with chronic liver disease or cirrhosis. To ensure effective surveillance, minimum standards have been established focusing on patient engagement, diagnostic accuracy, and system efficiency.
1. **Target Population**: Surveillance should be offered to individuals at high risk of HCC, including those with cirrhosis due to hepatitis B or C, alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD), and other chronic liver conditions.
2. **Surveillance Intervals**: Surveillance should be conducted at 6-month intervals, as evidence shows this frequency balances the benefits of early detection with resource utilization.
3. **Diagnostic Tools**: The recommended surveillance method is a combination of abdominal ultrasound and serum alpha-fetoprotein (AFP) testing. Ultrasound is the primary tool, while AFP serves as an adjunct to improve sensitivity. However, AFP alone is not sufficient due to its variability and limited specificity.
4. **Integrated Systems**: A robust, digital call-recall system is essential to track eligible patients and ensure timely surveillance. This system should automatically flag missed appointments and facilitate re-engagement.
5. **Patient Engagement**: Education and communication are critical to improve adherence. A multifaceted approach, including culturally sensitive materials, personalized reminders, and patient navigation support, can address barriers to participation.
6. **Quality Assurance**: Surveillance programs should have mechanisms for regular monitoring, auditing, and feedback to ensure adherence to guidelines and optimize outcomes.
By meeting these minimum standards, healthcare systems can enhance HCC surveillance, improve early diagnosis, and ultimately reduce mortality rates associated with this aggressive cancer.
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools are needed to identify high-risk patients who...
Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility criteria of clinical trials. This multicenter study...
Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of ALBI grade, EZ-ALBI grade, and sarcopenia in...
Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway. Why was...
Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety,...
Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients with underlying cirrhosis and portal hypertension. Why...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.